Testosterone
Department Releases Guidance on Implementing Testosterone Deficiency Screenings for Male Service Members
BLUF – The War Department has issued new clinical guidance requiring male service members age 30 and older to be screened for testosterone deficiency through symptom and risk-factor assessments during periodic health evaluations, with testing and individualized treatment—including testosterone replacement therapy when appropriate—available when clinically indicated; guidance for female service members will be issued separately. For Navy Medicine, the guidance establishes a standardized clinical pathway that primary-care providers will need to implement and monitor, making appropriate diagnosis, patient-provider decision-making and careful management of hormone therapy increasingly important components of force health and readiness.
Pentagon temporarily rescinds guidance on testosterone screening for US troops
BLUF – The Pentagon temporarily rescinded newly issued clinical guidance for mandatory testosterone-deficiency screening of service members age 30 and older, saying the document requires updates while interim guidance remains in effect; the withdrawn guidance had established separate screening and treatment pathways for men and women during annual health assessments. For Navy Medicine, the reversal creates near-term uncertainty for clinicians responsible for implementing the new hormone-screening policy and highlights the need to follow updated DHA guidance as screening, diagnostic and treatment requirements are refined.
Hegseth Wants a ‘High-T’ Military. Could That Pose Risks to Soldiers, or Society?
BLUF – The article examines the persistent belief that testosterone directly causes aggression and violence, concluding that decades of research show a far more nuanced picture: testosterone primarily amplifies behaviors that help individuals gain or maintain social status, whether through aggression, cooperation, generosity, or leadership, depending on the social context. For Navy Medicine, the review is particularly relevant as the Defense Department expands testosterone screening and treatment, underscoring the need for evidence-based counseling that avoids oversimplifying the hormone’s behavioral effects while helping service members understand both the potential benefits and limitations of testosterone therapy.
Widespread hormone replacement could yield long-term detriments that outweigh benefits
BLUF – Former VA Secretary David Shulkin argues that the Pentagon’s plan for widespread testosterone screening and hormone replacement therapy risks outpacing the available scientific evidence, warning that unnecessary treatment could expose service members to long-term health effects—including infertility, cardiovascular risks, and dependence on lifelong therapy—without clear proof of improved readiness or performance. For Navy Medicine, the commentary reinforces the importance of implementing endocrine care through evidence-based clinical guidelines, carefully balancing operational readiness goals against patient safety, informed consent, and long-term health outcomes.
Judge questions difference between Hegseth’s testosterone policy and transgender care for troops
BLUF – The article reports that a federal judge questioned the Pentagon about the apparent inconsistency between its new policy encouraging testosterone replacement therapy for service members with medically diagnosed low testosterone and its continued prohibition on hormone therapy for transgender troops, asking the government to explain the differing medical and legal rationales as part of ongoing litigation over the transgender service ban. For Navy Medicine, the case highlights the complex intersection of military personnel policy, endocrine care, and medical ethics, underscoring the need for clinicians to apply evidence-based standards consistently while implementing Department of Defense policy and supporting affected service members.